Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.60 |
| ▸ | JAK2 | O60674 | 4/20 | 0.60 |
| ▸ | JAK3 | P52333 | 3/20 | 0.60 |
| ▸ | SRC | P12931 | 7/20 | 0.59 |
| ▸ | ABL1 | P00519 | 3/20 | 0.55 |
| ▸ | ABL2 | P42684 | 2/20 | 0.55 |
| ▸ | KDR | P35968 | 4/20 | 0.54 |
| ▸ | RET | P07949 | 3/20 | 0.54 |
| ▸ | CDC7 | O00311 | 1/20 | 0.54 |
| ▸ | PLK4 | O00444 | 1/20 | 0.54 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.54 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.54 |
| ▸ | INSR | P06213 | 1/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | FYN | P06241 | 1/20 | 0.54 |
| ▸ | CDK1 | P06493 | 1/20 | 0.54 |
| ▸ | ROS1 | P08922 | 1/20 | 0.54 |
| ▸ | FER | P16591 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31574063 | 1.00 | EGFR (0.60) | EGFRJAK2JAK3SRCABL1 | |
| SCHEMBL29588418 | 1.00 | EGFR (0.60) | EGFRJAK2JAK3SRCABL1 | |
| SCHEMBL4824842 | 1.00 | EGFR (0.60) | EGFRJAK2JAK3SRCABL1 | |
| SCHEMBL29799663 | 1.00 | EGFR (0.60) | EGFRJAK2JAK3SRCABL1 | |
| SCHEMBL14706373 | 1.00 | EGFR (0.60) | EGFRJAK2JAK3SRCABL1 | |
| SCHEMBL1497755 | 0.94 | EGFR (0.68) | EGFRJAK2JAK3SRCABL1 | |
| SCHEMBL29351446 | 0.94 | EGFR (0.68) | EGFRJAK2JAK3SRCABL1 | |
| SCHEMBL29671261 | 0.94 | EGFR (0.68) | EGFRJAK2JAK3SRCABL1 | |
| SCHEMBL1497754 | 0.94 | EGFR (0.68) | EGFRJAK2JAK3SRCABL1 | |
| SCHEMBL4823191 | 0.94 | EGFR (0.68) | EGFRJAK2JAK3SRCABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152564-A1 | PROPYLENE KETONE-CONTAINING BIOINHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-05-15 | — | — | US | disclosed |
| US-20230374015-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KINNATE BIOPHARMA INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374015-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KINNATE BIOPHARMA INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374015-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KINNATE BIOPHARMA INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230303575-A1 | FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303575-A1 | FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303575-A1 | FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| WO-2023143514-A1 | PROPYLENE KETONE-CONTAINING BIOINHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2023-08-03 | — | — | WO | disclosed |
| CN-116514806-A | Biological inhibitor containing acrylketone, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-08-01 | — | — | CN | disclosed |
| EP-4169922-A1 | FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-04-26 | — | — | EP | disclosed |
| US-20160193210-A1 | ANTITUMOR DRUG FOR INTERMITTENT ADMINISTRATION OF FGFR INHIBITOR | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-07-07 | — | — | US | disclosed |
| EP-3023101-A1 | THERAPEUTIC AGENT FOR FGFR INHIBITOR-RESISTANT CANCER | Taiho Pharmaceutical Co., Ltd. (JP) | 2016-05-25 | — | — | EP | disclosed |
| EP-3023100-A1 | ANTITUMOR DRUG FOR INTERMITTENT ADMINISTRATION OF FGFR INHIBITOR | Taiho Pharmaceutical Co., Ltd. (JP) | 2016-05-25 | — | — | EP | disclosed |
| US-20160136168-A1 | THERAPEUTIC AGENT FOR FGFR INHIBITOR-RESISTANT CANCER | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-05-19 | — | — | US | disclosed |
| US-20160115168-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-04-28 | — | — | US | disclosed |
| EP-2947086-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2015-11-25 | — | — | EP | disclosed |
| US-9108973-B2 | 3,5-disubstituted alkynylbenzene compound and salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-08-18 | — | — | US | disclosed |
| US-20140343035-A1 | 3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF | TAIHO PHARMACEUTICAL CO.,LTD. (JP) | 2014-11-20 | — | — | US | disclosed |
| EP-2657233-B1 | 3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2014-08-27 | — | — | EP | disclosed |
| EP-2657233-A1 | 3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2013-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303575-A1 | FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | FGFR3, FGFR1, FGFR4 | EGFR 115/4885JAK2 21/4885JAK3 269/4885 |
| US-20230374015-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | FGFR1, FGFR2, FGFR3 | EGFR 8/4885JAK2 69/4885JAK3 251/4885 |
| US-20160136168-A1 | THERAPEUTIC AGENT FOR FGFR INHIBITOR-RESISTANT CANCER | FGFR1, FGFR3, FGFR4 | EGFR 14/4885JAK2 22/4885JAK3 241/4885 |
| US-20250152564-A1 | PROPYLENE KETONE-CONTAINING BIOINHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | CYP51A1, HSD17B7, CYP46A1 | EGFR 3337/4885JAK2 2995/4885JAK3 3990/4885 |
| US-20160193210-A1 | ANTITUMOR DRUG FOR INTERMITTENT ADMINISTRATION OF FGFR INHIBITOR | FGFR1, FGFR3, FGFR2 | EGFR 31/4885JAK2 9/4885JAK3 111/4885 |
| US-20140343035-A1 | 3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF | NFXL1, ZFX, CXXC5 | EGFR 1467/4885JAK2 23/4885JAK3 191/4885 |
| US-20160115168-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | BTK, JAK2, SYK | EGFR 839/4885JAK2 2/4885JAK3 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.